Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label,Multi-center Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Autologous T Cell Injection Targeting GPRC5D OriCAR-017 in Patients With Relapsed and/or Refractory Multiplemyeloma

NCT06182696 is registered in ClinicalTrials.gov with OriCell Therapeutics Co., Ltd. as lead sponsor.

NCT NCT06182696
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06182696 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label,Multi-center Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Autologous T Cell Injection Targeting GPRC5D OriCAR-017 in Patients With Relapsed and/or Refractory Multiplemyeloma
Lead sponsor
OriCell Therapeutics Co., Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
October 26, 2023
Completion date
August 31, 2028
Enrollment
83 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed and/or refractory multiple myeloma